Company intelligence / Profile preview

Techsomed

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Techsomed’s BioTraceIO is the first FDA-cleared ultrasound-based software for real-time tissue response prediction during liver tumor thermal ablation. Clinical studies demonstrated high accuracy (>90% match to 24-hour post-procedure CT) in predicting the extent of tissue damage, supporting improved precision and safety in minimally invasive oncology procedures. The company is expanding applications into cardiology and pain management.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: DeviceSoftware
Industry: Medical Imaging

Partnerships

GE HealthCare (field evaluation with Logiq™ ultrasound systems)Fraunhofer Mevis/Bremen subsidiary collaboration on image-guided solutionsLenovo partnership mentioned for technology deployment supportSCREEN Holdings investor/director involvement suggests strategic ties.

Beyond the preview

Go deeper on Techsomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Techsomed.

Explore the full profile